Nachrichten zur Eli Lilly & Co. Aktie

Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup

…

2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves

Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly boost…

Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.…

FDA approves Eli Lillys weight loss drug Zepbound for sleep apnea, expanding use in U.S.

The agencys decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader…

Healthcare Equity Strategist on Novo Setback

As Novo Nordisk experimental drug falls short of target, Mizuho Securities Healthcare Equity Strategist Jared Holz says Eli Lilly will…

Nvidia, Eli Lilly lead Fridays market cap stock movers By Investing.com

Nvidia, Eli Lilly lead Fridays market cap stock movers…

Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now

…

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

Todays sell-off in Novo Nordisk may be the buying opportunity youve been waiting for.…

Eli Lilly, Avago lead market cap stock movers this Friday By Investing.com

Eli Lilly, Avago lead market cap stock movers this Friday…

FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall By Investing.com

FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall…

Focus: In weight loss battle, Novo and Lilly face growing offensive from licenced copies

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented…

LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List

Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.…

Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls

Hims & Hers Health (HIMS) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in…

Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over By Investing.com

Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over…

Eli Lilly: FDA erklärt Engpass bei Tirzepatid für beendet – Rückenwind für Mounjaro und Zepbound

Eli Lilly sichert sich durch Innovation und starke Produkte wie Mounjaro und Zepbound einen führenden Marktanteil im boomenden Gewichtsabnahmesektor…

IBD 50s Hims & Hers Tumbles After FDA Pulls Lillys Weight-Loss Drug From Shortage List

Hims stock skidded Thursday after the FDA determined Eli Lillys tirzepatide — which sells as a weight-loss drug — is…

FDA says Eli Lillys weight loss drug Zepbound is no longer in shortage

The decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.…

Hims & Hers Health falls as FDA issues unfavorable compounded GLP-1 decision

Hims & Hers Health (NYSE:HIMS) is down 7% in early morning trading after the U.S. FDA determined that there is…

Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook

…

These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?

It isnt easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug…

This Is Huge News for Eli Lilly Investors @themotleyfool #stocks $LLY $NVO $HIMS

Eli Lilly just gave investors several reasons to cheer.…

This Is Huge News for Eli Lilly Investors

Eli Lilly just gave investors several reasons to cheer.…

Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug

When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to…

Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout

Dividend investors often prioritize stocks that have long track records for raising their payouts. But that can be a mistake.…

Eli Lillys Alzheimers treatment approved in China

Chinas medical regulator has approved Eli Lillys treatment for early Alzheimers, providing patients with another option after Eisai and Biogens…

Eli Lillys Alzheimers treatment approved in China By Reuters

Eli Lillys Alzheimers treatment approved in China…

Eli Lilly Alzheimer’s drug donanemab approved in China By Investing.com

Eli Lilly Alzheimer’s drug donanemab approved in China…

Eli Lilly: A Rare Buying Opportunity

…

4 Big Drug Stocks That May Continue to Outperform in 2025

Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum…

Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need…

2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious

As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is always providing…

Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. Theyre both leaders in the areas of…

2 Weight Loss Stocks That Are Screaming Buys in December

With drugs like Novo Nordisks Wegovy becoming household names over the last couple of years, its no surprise that there…

3 Unstoppable Stocks to Buy Right Now

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors…

Bernstein says Elon Musks pro GLP-1 stance may boost Eli Lilly, sees nearly 40% upside

The firm also has an outperform rating on the stock.…

Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its trading at close to…

Wall Street Sounds Alarm On Hims & Hers Amid Ro-Eli Lilly Zepbound Tie-Up: Retail Shrugs It Off

Shares of Hims & Hers Health Inc. slid to a three-week low on Wednesday before recovering some losses, even as…

Pharmakonzern Lilly erhöht Dividende und kündigt weiteren Aktienrückkauf an

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly plant in den kommenden Jahren weiter Aktien im Milliardenvolumen…

AKTIE IM FOKUS: Abnehmmittel-Liebling Lilly strauchelt - Dreimonatstief

NEW YORK (dpa-AFX) - Die im März 2023 losgetretene Rally der Eli-Lilly-Aktien ist am Mittwoch…

ROUNDUP: Pharmakonzern Lilly senkt Ausblick - Abnehm-Medikamente unter Erwartung

INDIANAPOLIS (dpa-AFX) - Der US-Pharmahersteller Lilly hat im vergangenen Quartal nicht an das starke erste…

Pharmakonzern Lilly senkt Ausblick - Abnehmmedikamente unter Erwartung

INDIANAPOLIS (dpa-AFX) - Der US-Pharmahersteller Lilly hat dank des Erfolgs seiner Diabetes- und Abnehmmedikamente Mounjaro…

ROUNDUP 2/Dank Abnehmmittel: Eli Lilly erhöht Jahresziele erneut - Kurssprung

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly hat im zweiten Quartal einen Umsatz- und Ergebnissprung…

Eli Lilly erhöht Jahresziele - Abnehmmittel treiben Geschäfte - Kurssprung

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly hat im zweiten Quartal einen Umsatz- und Ergebnissprung…

Eli Lilly kann in USA mit Alzheimer-Medikament bei Beratergremium punkten

WHITE OAK/INDIANAPOLIS (dpa-AFX) - Der US-Arzneimittelhersteller Eli Lilly kann weiter auf eine Zulassung seines Alzheimermittels…

Eli Lilly erhöht Jahresziele - Abnehmmittel treibt Geschäfte - Kurssprung

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly ist dank gut laufender Geschäfte mit Abnehmmitteln mit…

Pharmafirma Cheplapharm mit Rekordumsatz

GREIFSWALD (dpa-AFX) - Die Greifswalder Pharmafirma Cheplapharm ist weiter auf Wachstumskurs. Im Geschäftsjahr 2023 sei ein…

Zulassung von Lillys Alzheimer-Mittel könnte sich verzögern

INDIANAPOLS (dpa-AFX) - Der US-Arzneimittelhersteller Lilly muss womöglich noch länger auf eine Zulassung seines Alzheimermittels…

ANALYSE-FLASH: Jefferies hebt Ziel für Eli Lilly auf 853 Dollar - 'Buy'

NEW YORK (dpa-AFX Broker) - Das Analysehaus Jefferies hat das Kursziel für Eli Lilly nach…

ROUNDUP/Dank Abnehmmittel: Pharmakonzern Eli Lilly sieht weiteren Umsatzsprung

INDIANAPOLIS (dpa-AFX) - Nach dem Verkaufsstart seines Abnehmmittels traut sich der Pharmakonzern Eli Lilly 2024…

Dank Abnehmmittel: Pharmakonzern Eli Lilly sieht weiteren Umsatzsprung

INDIANAPOLIS (dpa-AFX) - Nach dem Verkaufsstart seines Abnehmmittels traut sich der Pharmakonzern Eli Lilly 2024…